Questioning the Veracity of Malawi’s $500 Million Cannabis Export Deal

In a recent article published by Malawi 24, a sensational claim has been made regarding a significant cannabis export deal between Malawi and North Macedonia. The article asserts that Malawi has secured an astonishing $500 million worth of cannabis biomass for export to North Macedonia. While this news has garnered attention, it is crucial to scrutinize the claims made and consider the apparent discrepancies in the figures.

First and foremost, let’s analyze the proposed numbers. The assertion that Malawi is set to export $500 million worth of cannabis biomass raises eyebrows for several reasons. To put it into perspective, if we assume that a kilogram of cannabis biomass costs around $990, which is a reasonable estimate, then 15,000 kilograms would indeed result in $14.85 million, far from the proclaimed $500 million. This massive discrepancy begs the question: what are we missing in this story?

Malawi’s decision to legalize cannabis farming for industrial and medicinal purposes in 2020 was driven by the aim to capitalize on the burgeoning global demand and shift away from tobacco as its primary export crop. Nevertheless, the alleged $500 million deal appears to be disproportionate, given the actual market dynamics.

North Macedonia, on the other hand, did make progressive changes in 2016 by amending its laws to permit the cultivation of cannabis for medical purposes and the production of cannabis oil and hemp seed. However, it’s worth noting that North Macedonia is not a major importer of cannabis, making the reported $500 million export figure even more implausible.

The discrepancy in numbers becomes more pronounced when considering the context of the global cannabis market. While there is a growing demand for medicinal cannabis, it remains a highly regulated industry, subject to stringent quality standards and a limited number of legitimate suppliers. North Macedonia, though open to medical cannabis cultivation, still strictly prohibits recreational use.

Among the potential off-takers for the Malawi Gold Cannabis biomass, Instadose Pharma, a Canadian brand, has been mentioned. Instadose Pharma, is recognized for its ambitious endeavor to establish a medical cannabis global distribution platform spanning across five continents, including Africa, Europe, Asia, South America, and North America. While their involvement as a potential off-taker is mentioned, more specifics about their role in the Malawi export deal remain to be clarified.

In light of these considerations, it is reasonable to question the accuracy of the claims made in the Malawi 24 article. The numbers simply do not add up, and the projected $500 million export figure appears to be inflated beyond reason. While it’s essential to acknowledge the efforts of Malawi’s government and the Cannabis Regulatory Authority in supporting the industry, the reported figures should be subjected to a more thorough and transparent scrutiny.

In conclusion, it is critical to approach sensational claims with a healthy dose of skepticism and to seek more detailed information and verification when dealing with such extraordinary figures. The reported $500 million cannabis export deal from Malawi to North Macedonia appears to lack a solid foundation, and the global cannabis market dynamics raise legitimate questions about the feasibility of such an agreement. That said, we want this to be true as it would be truly exhilarating for an African nation to secure such a deal.

Here is the article that was published by Malawi 24.